Top

Published in:

01-05-2020 | Rituximab | Clinical study

AEs increase economic burden in patients with CLL

Published in: Reactions Weekly | Issue 1/2020

Excerpt

Treatment-related adverse events (AEs) increase healthcare resource use (HRU) and costs in US patients with chronic lymphocytic leukaemia (CLL), according to findings of an AstraZeneca-funded study published in Advances in Therapy. …

2018 US dollars

Kabadi SM, et al. Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study. Advances in Therapy : 12 May 2020. Available from: URL: http://doi.oeg/10.1007/s12325-020-01350-w

Title: AEs increase economic burden in patients with CLL
Publication date: 01-05-2020
Publisher: Springer International Publishing
Keywords: Rituximab
Ibrutinib
Rituximab
Published in: Reactions Weekly / Issue 1/2020
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-020-78715-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

AEs increase economic burden in patients with CLL

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2020

Ketorolac

Heparin/protamine sulfate

Pembrolizumab

Ifosfamide

Prednisolone-acetate

Prednisone